June 2015 June 2015
New Product - Noxafil Concentrated Injection
Noxafil Concentrated Injection (posaconazole) is a broad spectrum triazole antifungal indicated for use in the treatment of the following invasive fungal infections in adults: invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy; fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. Noxafil is also indicated for the prophylaxis of invasive fungal infections among adults, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (HSCT) recipients. Noxafil Concentrated Injection is contraindicated with ergot alkaloids (ergotamine, dihydroergotamine), HMG‑CoA reductase inhibitors. Also contraindicated (although not studied in vivo or in vitro), is coadministration with certain drugs metabolised through the CYP3A4 system‑terfenadine, astemizole, cisapride, pimozide, and quinidine‑leading to potentially serious and/or life threatening adverse events, such as QT prolongation and rare occurrences of torsades de pointes. Noxafil Concentrated Injection is available as a Type I glass vial containing 16.7 ml of solution equivalent to 18 mg/ml of posaconazole.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au